Cancer Treatment and Research Communications (Jan 2020)

Emerging biomarkers in urothelial carcinoma: Challenges and opportunities

  • Nikolaos Andreatos,
  • Gopa Iyer,
  • Petros Grivas

Journal volume & issue
Vol. 25
p. 100179

Abstract

Read online

Advanced urothelial carcinoma (UC) is a very important cause of cancer-related morbidity and mortality with, until recently, only a few available therapeutic options. The treatment landscape has dramatically changed in recent years with the introduction of immune checkpoint inhibitors and the development of novel targeted agents, such as erdafitinib, and antibody-drug conjugates, such as enfortumab vedotin. Cost-effective utilization of this rapidly expanding therapeutic armamentarium can be further optimized via the identification and validation of reliable prognostic and predictive biomarkers that inform prognostication and patient selection. In this review, we aim to summarize examples of recent developments in the rapidly expanding field of emerging biomarkers in UC, outlining challenges and opportunities.

Keywords